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Abstract
Background: Muntingia calabura L. (family Muntingiaceae), commonly known as Jamaican cherry or kerukup siam
in Malaysia, is used traditionally to treat various ailments. The aim of this study is to elucidate the possible
underlying gastroprotective mechanisms of ethyl acetate fraction (EAF) of Muntingia calabura methanolic leaves
extract (MEMC).
Methods: MEMC and its fractions were subjected to HPLC analysis to identify and quantify the presence of its
phyto-constituents. The mechanism of gastroptotection of EAF was further investigated using pylorus ligation-
induced gastric lesion rat model (100, 250, and 500 mg/kg). Macroscopic analysis of the stomach, evaluation of
gastric content parameters such as volume, pH, free and total acidity, protein estimation, and quantification of
mucus were carried out. The participation of nitric oxide (NO) and sulfhydryl (SH) compounds was evaluated and
the superoxide dismutase (SOD), gluthathione (GSH), catalase (CAT), malondialdehyde (MDA), prostaglandin E2
(PGE2) and NO level in the ethanol induced stomach tissue homogenate was determined.
Results: HPLC analysis confirmed the presence of quercetin and gallic acid in EAF. In pylorus-ligation model, EAF
significantly (p <0.001) prevent gastric lesion formation. Volume of gastric content and total protein content
reduced significantly (p < 0.01 and p < 0.05, respectively), while free and total acidity reduced in the doses of 250
and 500 mg/kg (p <0.001 and p <0.05, respectively). EAF also augmented the mucus content significantly (p < 0.001).
Pre-treatment with N-nitro-L-arginine methyl ester (L-NAME) or N-ethylmaleimide (NEM) reversed the gastroprotective
activity of EAF. EAF treatment markedly ameliorated the SOD, GSH and CAT activity and PGE2 and NO level while
attenuating MDA level, relative to the vehicle group.
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Conclusions: In conclusion, the underlying gastroprotective mechanisms of EAF could be associated with the
antisecretory, participation of mucus, antiperoxidative, improvement of antioxidant status, modulation of NO and SH
compounds, stimulation of PGE2 as well as presence of quercetin and gallic acid.
Keywords: Muntingia calabura, Fraction, Gastric ulcer, Antisecretory, Antioxidant, Nitric oxide, Sulfhydryl compound,
Prostaglandin, Quercetin, Gallic acid
Background
Gastric ulcer is one of the major gastrointestinal disor-
ders that affect considerable number of people around
the world, while growing in occurrence and prevalence
globally [1]. Some authors refer to gastric ulcers as the
new “plague” of the 21st century [2]. It has been pro-
jected that 14.5 million of the worldwide population are
affected by gastric ulcers with a mortality rate of 4.08
million [3]. The pathophysiology of gastric ulcer is asso-
ciated with the imbalance between aggressive and pro-
tective factors in the stomach. Gastric mucosal damage
occurs when noxious factors “overwhelm” an intact mu-
cosal defense, or weakening of the mucosal defensive
mechanisms [4]. The noxious factors in this context in-
clude alcohol ingestion, acid and pepsin secretion, poor
diet, stress, reactive oxygen species (ROS), the use of
non-steroidal anti-inflammatory drugs (NSAIDs) and
Helicobacter pylori infection [5, 6]. On the other hand,
the key defense factors and mechanisms that afford mu-
cosal defense include sufficient mucus secretion and
mucosal blood flow, bicarbonate secretion, intact mucus
barrier, prostaglandins, surface active phospholipids, in-
creased levels of antioxidants, activity of anti-
inflammatory compounds and adequate levels of nitric
oxide (NO) [6–8].
Currently, the prevention and treatment of gastric ul-
cers has gained lots of interest and became and import-
ant challenge confronting medicine nowadays. To date,
there are a few approaches used to prevent gastric ulcer-
ation, which include potentiation of the mucosal defense
together with reduction of acid secretion and its
neutralization, stimulation of gastric mucin synthesis,
enhancement of antioxidant levels in the stomach, and
inhibition of Helicobacter pylori growth [9]. Secretion of
gastric acid is believed to be the central component of
gastric ulcers despite the presence of many causative fac-
tors [7] and therefore, inhibition of gastric acid secretion
tend to be the key therapeutic target for ulcer diseases
[10]. On the other hand, another key factor in the patho-
genesis of gastric ulcers is the production of reactive
oxygen species (ROS). The production of ROS and a
concomitant reduction of antioxidant capacity causes
damage to the essential cell constituents, which are pro-
teins, lipids and nucleic acids, resulting in the formation
of toxic compounds and causes cell death due to their
extreme reactivity [8, 11]. Therefore, controlling the
ROS formation and gastric acid secretion are essential
for the treatment of these pathologies [12].
The current medicinal treatment of gastric ulcers in-
clude acid blockers that reduce acid secretion, proton
pump inhibitors, antibiotics to eradicate Helicobacter
pylori and tissue lining protecting agents such as sucral-
fate and bismuth cholinergics [13, 14]. Eventhough these
drugs have decreased the morbidity rates, but they are
often associated with undesirable adverse effects such as
hypersensitivity, impotence, arrhythmia, hematopoietic
disorders, gynecomastia and antibiotic resistance in the
long run [15, 16]. Furthermore, these available drugs also
have high relapse rate, low efficacy in gastric ulcers
treatment and are often costly [5, 9, 10]. Hence, there is
a pressing need to discover a more effective and safe al-
ternative therapies to treat gastric ulcers. In this context,
the use of medicinal plants has gained interest and cap-
tured the attention of many researchers. Plant extracts
can be valuable and serve as a new source of therapeu-
tics in the treatment of gastric ulcers whereby antisecre-
tory, cytoprotective and antioxidant activities, isolated or
in combination, are the three main functions of a gastro-
protective agent, which play the key role in gastric mu-
cosal protection [17].
The plant Muntingia calabura L. (family Muntingia-
ceae), commonly known as Jamaican cherry or kerukup
siam in Malaysia, is widely distributed throughout the
warm areas of Asian region [18]. Several medicinal uses
have been documented on various parts of this tree in
East and Southeast Asia as well as tropical America.
Muntingia calabura's leaves, flowers, barks and roots
have been used as a folk remedy to treat headaches,
fever and incipient cold. According to Peruvian folklore,
the leaves are used to provide relief from gastric ulcers
and to reduce swelling of the prostate gland [19]. Be-
sides, they are also employed as antiseptic, antispas-
modic, and antidyspeptic agent [20, 21].
On the other hand, Muntingia calabura is reported to
possess a broad range of pharmacological activities,
which have been proven scientifically. This include anti-
tumor [20, 22], antibacterial [23], antinociception [19,
24, 25], anti-inflammatory, antipyretic [25], antioxidant
and antiproliferative [26] activities exhibited by the
leaves of Muntingia calabura, while several types of
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compounds have been isolated and identified from the
leaves, roots and stem barks of Muntingia calabura
[20–22, 27, 28]. Various phytochemicals have been de-
tected in the leaves of Muntingia calabura such as flavo-
noids, saponins, tannins and triterpenes [29].
In our previous study, we have reported the gastropro-
tective activity of several fractions obtained from crude
methanol extract of Muntingia calabura (MEMC) leaves
against ethanol-induced gastric lesion in rats [30]. From
our study, we have found that ethyl acetate fraction
markedly ameliorate gastric ulceration and exerted the
most effective protection as compared to the other frac-
tions. Therefore, the present study was aimed to deter-
mine the mechanism of action underlying the
prophylactic effect of the ethyl acetate fraction derived
from MEMC against gastric lesions in rats.
Pylorus-ligation model used in this study is one of the
most widely used models to study the effect of drugs on
gastric acid and mucus secretion. Ulcers developed by li-
gating the pyloric end of the stomach are caused by in-
crease in gastric hydrochloric acid (HCl) secretion and/
or stasis of acid, leading to auto digestion of the gastric
mucosa and breakdown of the gastric mucosal barrier
[31]. Therefore, agents that are able to increase mucus
secretion (cytoprotective) and/or reduce secretion of
gastric aggressive factors such as pepsin and acid are ef-
fective gastroprotective agents [32]. On the other hand,
the ethanol-induced ulcer model is useful for studying
the efficacy of potential drugs or testing agents that have
cytoprotective and/or antioxidant activities [33].
Methods
Chemicals
The chemicals used in this study are of analytical grades
and had been prepared immediately before use. The fol-
lowing drugs were used: ranitidine (Sigma Aldrich,
USA), absolute ethanol (Fischer Scientific, USA), N-
ethylmaleimide (NEM) (Sigma-Aldrich, USA), NG-nitro-
l-arginine methyl esters (L-NAME) (Sigma-Aldrich,
USA), carbenoxolone (CBX) (Sigma-Aldrich, USA) and
diethyl ether (Fischer Scientific, USA).
Plant material
Muntingia calabura leaves were collected from their
natural habitat in Shah Alam, Selangor, Malaysia, be-
tween May and August 2010. The plant was identified
by a botanist from the Institute of Bioscience (IBS), Uni-
versiti Putra Malaysia (UPM), Serdang, Selangor. A vou-
cher specimen, SK 2466/14, has been deposited at the
UPM IBS Laboratory of Natural Products Herbarium.
Extraction and fractionation of Muntingia calabura leaves
Method described by Zakaria et al. [26] and Sufian et al.
[28] was employed to prepare the crude extract of
Muntingia calabura leaves and its fractions, respectively.
Five hundred grams of matured leaves were air-dried at
room temperature (27 ± 2 °C) for 1–2 weeks and ground
into fine powder. Methanol (MeOH) was used as the
solvent for extraction. The powder was soaked in MeOH
at a ratio of 1:20 (w/v) for 72 h. The mixture was filtered
using filter funnel, cotton and Whatman No. 1 filter
paper. The soaking and filtration were repeated on the
residue for twice. The filtrate collected from each extrac-
tion was pooled and evaporated in a rotary evaporator at
40 °C under reduced pressure to obtain methanol extract
of Muntingia calabura (MEMC). The dried crude ex-
tract was suspended in MeOH and distilled water
(dH2O) water in the ratio of 1:2 to afford an aqueous
MeOH solution. The mixture was sequentially parti-
tioned with different solvents, which were petroleum
ether and ethyl acetate, yielding petroleum ether fraction
(PEF), ethyl acetate fraction (EAF). The fractions were
filtered and evaporated to dryness under vacuum using
rotary evaporator. MEMC, PEF and EAF were subjected
to HPLC to quantify the compound of interest, which
could be associated with the extract’s gastroprotective
effect.
Identification and quantification of phytoconstituents
present in EAF by HPLC
Method described by Zakaria et al. [34] with slight mod-
ifications was adapted to carry out the HPLC analysis of
EAF. Briefly, 10 mg of sample was suspended in 1 ml
methanol. The solutions were filtered through a filter
cartridge (pore size of 0.45 μm) prior to use. The sample
was analysed using a HPLC system (Waters Delta 600
with 600 Controller) with photodiode array detector
(PDA) (Waters 996). A C18 column (4.6 mm i.d. ×
250 mm) packed with 5 μm diameter particles was used.
The mobile phase was water containing 0.1 % formic
acid (A) and acetonitrile (B). Initial conditions were
85 % A and 15 % B with a linear gradient reaching 25 %
B at t = 12 min. This condition was maintained for
10 min. B was reduced back to 15 %, the initial condi-
tion, and was maintained until t = 35 min. At t =25 min,
the programme returned to the initial solvent compos-
ition. The flow rate was 1.0 ml/min, injection volume
was 10 μl and the wavelength were 280 nm for gallic
acid and 330 nm for quercetin. The column oven was
set at 27 °C. Stock solutions of standards references were
prepared in methanol at concentration 1 mg/ml. The
chromatography peaks were confirmed by comparing its
retention time with those of reference standards and by
the respective UV spectra. Calibration curve for gallic
acid was Y = 29562x + 102777 (R2 = 0.9969) and quer-
cetin was Y = 43236x – 81458 (R2 = 0.999). All chroma-
tography operations were carried out at ambient
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temperature and in triplicate. The HPLC analysis was
carried out in the Laboratory of Phytomedicine, Medi-
cinal Plants Division, Forest Research Institute of
Malaysia (FRIM), Kepong, Malaysia.
UHPLC–ESI analysis
The UHPLC system was performed on a Dionex 3000
UHPLC system acquired from Thermo Fisher Scien-
tific (USA) that consisted of an autosampler equipped
with a column oven, a tray compartment cooler, and
a binary pump with built in solvent degasser. The
chromatographic separation was performed on a BEH
C18 UHPLC column, 100 mm x 2.5 μm, 1.7 μm
(WATERS) at a flow rate of 0.3 mL/min. The mobile
phases used were (A) 0.1 % formic acid in water and
(B) 0.1 % formic acid in acetonitrile. The gradient
started with 10 % mobile phase B, reaching 20 % mo-
bile phase B at 5 min, 60 % mobile phase B at
17.0 min, at isocratic elution of 90 % B for 3 min.
The gradient reached the initial conditions were held
for 2 min as a re-equilibration step. The injection
volume was 10 μL and the column temperature was
maintained at 40 °C. The UHPLC system was coupled
to a linear ion-trap-Orbitrap mass spectrometer Q
Exactive from Thermo Fisher Scientific (U.S.A)
equipped with an electrospray ionization (ESI) source.
The mass detection was performed in a range of 150-
1500 m/z. The ESI source was operated in negative
ion mode under the following specific conditions:
source voltage, 3.2 kV; sheath gas, 35 arbitrary units;
auxiliary gas, 15 arbitrary unit; sweep gas, 10 arbitrary
unit; and capillary temperature, 320 °C. Nitrogen
(>99.98 %) was employed as sheath gas, auxiliary and
sweep gas. Instrument control and data acquisition
were performed with Chameleon 6.8 software and
Xcalibur 2.2 software (Thermo Fisher Scientific).
Animals
The experiments were performed on male Sprague
Dawley rats (180–200 g; 8–10 weeks old). They were
obtained from the Animal Unit, Faculty of Medicine
and Health Sciences, UPM, Malaysia. The animals
were kept in polypropylene cages with wood shaving,
fed with standard pellet and allowed free access to
water. They were kept in room temperature (27 ± 2
0C; 70–80 % humidity; 12 h light/darkness cycle) in
the Animal Holding Unit (UPM). Prior to all assays,
the rats were fasted. Standard drugs and MEMC were
administered orally (p.o.) by gavage with 8 % Tween
80 (10 ml/kg) as the vehicle. The use of animals in
this study was approved by the Animal Care and
Used Committee (ACUC) of UPM (Approval No:
UPM/FPSK/PADS/BR-UUH/00474).
Determination of the mechanism underlying the
gastroprotective activity of EAF
Pyloric ligation
Method by Shay et al. [35] with slight modifications was
employed to perform pyloric ligation. Rats were ran-
domly divided into 5 groups, with six rats in each group.
Group-I was the control group administered with 8 %
Tween 80 (vehicle) orally (p.o), Group-II was the posi-
tive control administered with ranitidine at 100 mg/kg
(p.o), while for Group-III,-IV and-V, rats were adminis-
tered with EAF (100, 250 and 500 mg/kg, respectively).
Pylorus ligation was performed on 48 h fasted rats 1 h
after the administration of the test compounds. Under
light anesthesia induced using ketamine HCl (100 mg/kg,
intramuscular) and xylazine HCl (16 mg/kg, intramuscu-
lar), a 2 cm long mid-line abdominal incision was per-
formed, just below the sternum. The pyloric portion of
the stomach was gently mobilized and carefully ligated
with a silk ligature around the pyloric sphincter in a tight
knot. Care was taken while tying the knot to avoid inter-
ference with gastric blood supply. The abdominal incision
was sutured, the skin was cleaned of any blood spots or
bleeding and the animals were allowed to recover from
anesthesia.
Assessment of gastric mucosal lesion
The animals were sacrificed 6 h after ligation by expos-
ure to diethyl ether and cervical dislocation. The sto-
machs were removed, and the contents were drained
out, collected, and centrifuged. The stomach was opened
along the greater curvature to determine the lesion dam-
age as described by Balan et al. [36]. The percentage
protection was calculated using the following formula:
Protection %ð Þ ¼ UA control – UA pre‐treated groupð Þ
UA controlð Þ  100%
Determination of volume, pH, free and total acidity of
gastric content
The drained gastric content was centrifuged for 10 min
at 2500 rpm to remove any solid debris. The volume
and pH of the gastric juice was measured. The gastric
juice was also subjected to free and total acidity estima-
tion according to method described by Srivastava et al.
[37]. Titration with 0.01 N NaOH with methyl orange
reagent was carried out until the color of the solution
became yellowish in order to determine the free acidity.
The volume of alkali added was noted. Then, two to
three drops of phenolphthalein was added to the solu-
tion. The solution was titrated until definite red tinges
appear. The total volume of NaOH added was noted.
This volume corresponds to total acidity. Acidity was
calculated using the following formula:
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The total protein content in gastric juice was estimated
by Lowry’s method, adapted from Lowry et al. [38] using
alkaline copper reagent and Folin’s reagent. The color
developed was read at 660 nm. The protein content was
calculated from the standard curve prepared with bovine
serum albumin and protein concentration was expressed
as mg/ml of gastric juice.
Estimation of gastric wall mucus content
Method described by Corne et al. [39] with slight modi-
fications was employed to determine the gastric wall
mucus content. The stomach was opened along the
greater curvature, weighed, and immersed in 10 ml of
0.1 % Alcian blue (0.16 M sucrose in 0.05 M sodium
acetate, pH 5.8) for 2 h. The stomach was then rinsed
twice in 0.25 M sucrose solution (15 min each) to re-
move the excessive dye. The remaining dye that com-
plexed with the gastric mucus was extracted with 0.5 M
MgCl2. The glandular segment remained in this solution
for 2 h with intermittent agitation for 1 min in every
30 min interval. The resultant blue extract was then
shaken vigorously with an equal volume of diethyl ether
until the formation of an emulsion. The resulting emul-
sion was centrifuged for 10 min at 3600 rpm. The ab-
sorbance of the aqueous layer was read at 580 nm using
a spectrophotometer. The concentration of Alcian blue
was calculated through a standard curve and the results
were expressed in mg of Alcian blue/g of wet tissue.
Ethanol-induced gastric mucosal lesion in L-NAME or NEM
pre-treated rats
The role of endogenous NO and the involvement of sulf-
hydryl (SH) compounds in the gastroprotective effect of
EAF were evaluated using the method described by
Takayama et al. [40]. Male rats were divided into 9
groups and pretreated (i.p.) with saline, L-NAME (N-ni-
tro-L-arginine methyl ester, 70 mg/kg) an inhibitor of the
NO synthesis or NEM (N-ethylmaleimide, 10 mg/kg) a SH
compound blocker. Thirty minutes after the pre-treatment,
the animals were administered (p.o.) vehicle (8 % Tween
80), carbenoxolone (100 mg/kg) or EAF (500 mg/Kg). Sixty
minutes later, all groups received absolute ethanol (5 ml/kg,
p.o) to induce gastric ulcers. All the rats were sacrificed 1 h
after the administration of ethanol by exposure to diethyl
ether and cervical dislocation. The stomach was removed
and gastric damage was determined as described above.
Since EAF exhibited a dose-dependent effect and exerted
substantial protective action against gastric mucosa in the
ethanol-induced gastric ulcer model, the highest effective
dose (500 mg/kg) was used for this study.
Biochemical analysis
Measurement of superoxide dismutase (SOD), glutathione
(GSH) level and catalase (CAT) activity
Stomach tissues of the rats pre-treated with vehicle (8 %
Tween 80), ranitidine (100 mg/kg) or EAF (100, 250 and
500 mg/kg) followed by ulcer induction using absolute
ethanol for 1 h were used for the determination of SOD,
GSH level and CAT activity. Gastric tissue was cut into
pieces and the exact weight was recorded. The tissues
were homogenized with a homogenizer using appropri-
ate cold buffer and then were centrifuged at 10000 g for
15 min at 4 °C. The supernatants were used to deter-
mine the activities of CAT and levels of SOD, and GSH.
The concentration of protein in the supernatants was
measured by the Bradford method [41] using bovine
serum albumin (BSA) as a standard. Levels of SOD,
GSH and CAT were determined using the commercial
assay kits according to the manufacturer’s instructions,
respectively (Superoxide Dismutase Assay Kit, Glutathi-
one Assay Kit and Catalase Assay Kit, Cayman Chemical
Company, Ann Arbor, MI, US).
Measurement of malondialdehyde (MDA) level
MDA levels were measured in stomach tissues obtained
from the ethanol-induced gastric ulcer. The stomach tis-
sue was homogenized and centrifuged as described be-
fore and the supernatant was used for determination of
MDA by using an enzyme-linked immunosorbent assay
kit (USCN Life Science Inc., Atlanta, GA, USA). The op-
tical densities were measured at 450 nm and the results
were expressed as ng/mg protein.
Determination of prostaglandin E2 (PGE2)
PGE2 levels were determined in stomach tissues ob-
tained from the ethanol-induced gastric ulcer. The
supernatant of homogenized and centrifuged stomach
tissue was used for determination of PGE2 by using
Prostaglandin E2 Express EIA Kit (Cayman Chemical
Company, Ann Arbor, MI, US). The optical densities
were measured at 412 nm. The PGE2 concentrations
were normalized by protein contents and the results
were expressed as pg/mg protein.
Determination of NO level
NO level in the gastric mucosa was evaluated as total ni-
trate/nitrite levels using Griess reagent [42]. In brief, the
stomach homogenates were prepared in 50 mM potas-
sium phosphate buffer (pH 7.8). The homogenates were
centrifuged at 4000 rpm for 10 min at 4 °C. Fifty micro-
liter of Griess reagent (0.1 % N-(1-naphthyl) ethylenedia-
mide dihydrochloride, 1 % sulfanilamide in 5 %
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phosphoric acid) was added to 50 μL supernatant and the
absorbance was measured at 540 nm after 10 min. Sodium
nitrite was used as the standard in this assay to generate
the standard curve.
Statistical analysis
The results were expressed as mean ± standard error
mean (SEM) and analyzed using One Way Analysis of
Variance (ANOVA), followed by Dunnett’s post hoc
test or the Newman-Keuls test. Results were consid-
ered significant when p < 0.05.
Results
Identification and quantification of gallic acid and
quercetin
HPLC fingerprinting of MEMC, PEF and EAF revealed the
presence of the gallic acid at λmax 216.6–272.0 nm and
quercetin at λmax 255.5–370.6 nm (Fig. 1a and b). Spiking
of these compounds in MEMC, PEF or EAF increased the
peak area, corresponding to the same λmax value of the
compounds. The quantification result presented in Table 1
shows that EAF contains the highest amount of gallic acid
(39.89 ± 0.96 mg/g extract) and quercetin (9.36 ± 0.29 mg/g




Fig. 1 a and b: HPLC analysis of MEMC, PEF and EAF carried out at the wavelength 330 nm revealed the presence of the quercetin at λmax 255.5-
370.6 nm at RT 3.696 min. Spiking of quercetin with the extracts increased the peak area, corresponding to the same λmax value of the compounds. c
and d:HPLC fingerprinting of MEMC, PEF and EAF at the 280 nm wavelength revealed the presence of the gallicacid at λmax 216.6-272.0 nm at RT
4.204 min. Spiking of gallic acid with the extracts increased the peak area, corresponding to the same λmax value of the compounds
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Identification of phenolic compounds in EAF
EAF was analysed based on the accurate mass data of
the molecular ions, in which ions detected were tenta-
tively identified by their generated molecular formula,
through the software Data analysis (Xcalibur) which pro-
vided list of possible elemental formulas, together with
the use of standard when available and after thorough
survey of the literature. The widely accepted accuracy
threshold for confirmation of elemental compositions
was established at 5 ppm. The UHPLC-ESI analysis of
EAF revealed the presence of 22 phenolic compounds
(Table 2) which list the peak number, retention time, ob-
served m/z, the generated molecular formula and the
proposed compound detected. Figure 2 corresponds to
the base peak chromatogram in negative ion, with the
molecule structure of ermanin, kaempferide, pinobaksin
and pinostrobin in Fig. 3.
Pylorus ligation-induced gastric lesion
As reported in Fig. 4, EAF at the doses of 100, 250,
and 500 mg/kg exerted gastroprotective effect by pre-
venting the development of gastric lesion in a dose
related manner. Oral administration of EAF at the
abovementioned doses decreased lesion area signifi-
cantly by 8.0 ± 1.5, 3.8 ± 0.8, and 1.7 ± 0.6 mm2, respect-
ively, affording 67.8, 84.6 and 93.3 % protection in
comparison to the control, 24.8 ± 2.0 mm2 (p <0.001). Ra-
nitidine (100 mg/kg), the standard drug used as the posi-
tive control in the study significantly inhibit the formation
of gastric lesion by 1.2 ± 0.4 mm2 (95.3 % protection) as
compared to the control group.
Evaluation of gastric juice parameters
Table 3 shows the effects of EAF upon baseline acid se-
cretion collected after 6 h of pylorus ligature in rats.
EAF, at all the three doses (100, 250, and 500 mg/kg)
significantly decreased the volume of gastric secretion by
56 % (p <0.01), 76 % (p <0.001) and 48 % (p <0.01), re-
spectively. All the doses of EAF augmented the pH value
Table 1 Gallic acid and quercetin’s composition in MEMC and
its active fractions (PEF and EAF) at mg/1 g of extract. Results
are expressed as mean ± standard deviations (SDs) of three
determinations
Compounds MEMC PEF EAF
Gallic acid (mg/g) 11.97 ± 0.27 3.40 ± 0.01 39.89 ± 0.96
Quercetin (mg/g) 4.83 ± 0.16 8.81 ± 0.44 9.36 ± 0.29
Table 2 Phenolic compounds identified in EAF by UHPLC-MS
Peak No tR (min) [M-H]- Error (ppm) Formula Identification
1. 0.45 169.01376 3.433 C7H5O5 Gallic acid
2. 2.34 163.03978 4.964 C9H7O3 Protocatechuic acid
3. 3.10 193.05020 3.443 C10H9O4 Ferulic acid
4. 4.53 599.10547 3.879 C28H23O15 Quercitrin-2″-O-gallate
5. 4.93 939.11377 4.220 C41H31O26 Pentagalloyl-hexoside II
6. 5.05 447.09421 4.523 C21H19O11 Kaempferol-3-O-galactoside
7. 5.31 317.0308 5.130 C15H9O8 Myricetin
8. 6.20 193.08661 3.569 C10H9O4 Isoferulic acid
9. 6.91 583.11053 3.941 C28H23O14 Afzelin-O-gallate
10. 7.35 301.03586 4.023 C15H9O7 Quercetin
11. 7.42 603.07928 3.894 C30H19O14 Quercetin dimer
12. 7.67 255.06636 4.605 C15H11O4 Pinocembrin
13. 8.14 593.13116 3.697 C30H25O13 Kaempferol-3-O-glucoside
14. 8.18 315.05196 6.478 C16H11O7 Rhamnetin
15. 8.55 271.06094 3.099 C15H12O5 Pinobaksin
16. 8.94 285.04037 3.528 C15H9O6 Kaempferol
17. 10.80 253.05063 4.326 C15H9O4 Chyrsin I
18. 11.67 253.05099 5.749 C15H9O4 Chyrsin II
19. 11.91 299.05597 3.195 C16H11O6 Kaempferide
20. 12.56 313.07245 5.703 C17H13O6 Ermanin I
21 12.78 313.07230 5.224 C17H13O6 Ermanin II
22. 13.32 269.08194 4.105 C16H13O4 Pinostrobin
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Fig. 2 Total ion chromatography (TIC) of the indicatedEAF sample, obtained from the UHPLC instrument in negative ion mode
Fig. 3 MS spectra and structure of ermanin, kaempferide,pinobaksin andpinostrobin detected in the Muntingia calabura ethyl acetate fraction
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eventhough they were not significantly different as com-
pared to the negative control. On the other hand,
the free and total acidity of EAF reduced signifi-
cantly at the doses of 250 and 500 mg/kg by about
39 % (p <0.001) and 25 % (p <0.05), respectively, for
free acidity and 40 % (p <0.001) and 20 % (p <0.05),
respectively, for the total acidity. Meanwhile, the
lowest dose of EAF (100 mg/kg) failed to signifi-
cantly decrease the free and total acidity of the gas-
tric secretion. Besides, oral administration of EAF in
all the three doses also resulted in significant reduc-
tion in total protein content present in the gastric
secretion by 21 % (p < 0.01), 15 % (p < 0.05), and 17 %
(p < 0.05), respectively, in comparison to the control
group. Ranitidine (100 mg/kg), the reference drug used in
the assay caused a reduction in the volume of gastric se-
cretion by 71 % (p < 0.001), increased the pH by about 2.2
folds (p < 0.001), decreased the free and total acidity of the
gastric juice by about 49 % (p < 0.001) and reduced the
total protein content by 31 % (p < 0.001) as compared to
the control group. The EAF showed a dose-dependent
gastroprotective activity as the highest tested dose
(500 mg/kg EAF) was significantly more effective in pro-
tecting the gastric wall as compared to the lowest dose
(100 mg/kg EAF). In contrast, EAF showed no dose re-
sponse in the antisecretory activity as the 250 mg/kg dose
showed maximum reduction in volume of gastric juice.
Besides, there was also a significant difference of free and
total acidity when 100 mg/kg EAF was compared to
250 mg/kg EAF, but not 500 mg/kg EAF.
Determination of mucus in the gastric mucosa
Pre-treatment of EAF significantly augmented the gastric
wall mucus content in all the doses administered (100,
250, and 500 mg/kg) as observed in Fig. 5. Oral adminis-
tration of the extract and ranitidine increased the mucus
content significantly (p <0.001) when compared with the
control animals pre-treated with vehicle alone.
Effect of L-NAME and NEM pre-treatment in EAF
gastroprotection
In order to determine if NO and SH compounds are
likewise involved in the mechanism of action of EAF, the
animals were pre-treated with L-NAME (70 mg/kg) or
NEM (10 mg/kg), respectively. Pre-treatment with L-
NAME or NEM aggravated the gastric lesions signifi-
cantly (p <0.001) as compared to the vehicle in the saline
group. The administration of L-NAME or NEM signifi-
cantly increased the effects of ethanol on gastric mucosa
injury, resulting in the loss of the gastroprotection of
EAF (Fig. 6). These results suggested that the gastropro-
tective effect of EAF implicated a strong participation of
the NO and SH compounds that are relevant in the mu-
cosal protection against harmful injuries
Effect of EAF on SOD, GSH, MDA levels and CAT activity
in the stomach tissue of the ethanol-treated rats
The effect of EAF on SOD, GSH, MDA levels and
CAT activity in ethanol-treated stomach tissue ho-
mogenates is presented in Table 4. Oral administra-
tion of ethanol decreased their gastric SOD and
GSH levels and CAT activities significantly. The
Fig. 4 Effect of oral administration of vehicle (Tween 80, 8 %),
ranitidine (100 mg/kg) or EAF (100, 250, and 500 mg/kg) on pylorus
ligation-induced ulcer. The ulcerated area (mm2) was expressed as
Mean ± SEM for 6 animals. One way ANOVA was followed by
Dunnett's post hoc test, ***p < 0.001 vs. vehicle
Table 3 Effect of EAF on gastric juice parameters in pylorus-ligated rat model
Treatment Volume of gastric juice (ml) pH Free acidity (meq/l) Total acidity (mEq/l) Total protein (mg/ml)
Control (8 % tween 80) 7.75 ± 1.18 1.26 ± 0.08 103.30 ± 7.53 142.50 ± 9.69 5.45 ± 0.17
Ranitidine 2.25 ± 0.38*** 2.73 ± 0.38** 52.67 ± 5.70*** 80.67 ± 7.87*** 3.78 ± 0.28***
EAF 100 mg/kg 3.38 ± 0.86** 1.97 ± 0.31 97.00 ± 8.42 128.70 ± 4.22 4.32 ± 0.31**
250 mg/kg 1.83 ± 0.23*** 1.94 ± 0.20 62.83 ± 7.08*** 99.00 ± 6.46*** 4.61 ± 0.10*
500 mg/kg 4.02 ± 0.64** 1.69 ± 0.25 77.50 ± 3.43* 115.20 ± 4.80* 4.50 ± 0.13*
Values are expressed as mean ± SEM for six animals in each group. One way ANOVA was followed by Dunnett's post hoc test, *p < 0.05, **p < 0.01, and ***p <
0.001 as compared to the control group
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depleted levels or activity of SOD, GSH and CAT
were restored significantly by EAF (100, 250 and 500 mg/
kg) and ranitidine treatments, parallel to the normal
group. On the other hand, there was a significant in-
crease in the gastric MDA content of the ethanol
treated group of rats when compared with the nor-
mal untreated rats. Treatments of EAF at the doses
of 100, 250 and 500 mg/kg to ethanol treated rats
decreased the elevated MDA levels significantly;
similar to the standard ranitidine treatment, and
comparable to the normal rats. Thus, the observation
indicated that EAF might attenuate the changes caused by
ethanol via regulation of oxidant–antioxidant balance.
Effect of EAF on PGE2 levels
The decreased level of PGE2 (p <0.01) in the vehicle
group when compared to that of the normal control
group indicated that ethanol treatment reduced the
PGE2 production. Administration of rats with EAF at
doses of 250 and 500 mg/kg significantly (p <0.001)
increased the level of PGE2. Table 5 shows that EAF
was able to maintain a high PGE2 level in the rats
despite being treated with ethanol, similar to the con-
trol rats. The low dose of EAF, 100 mg/kg, also led
to an increment in PGE2 level, though the variation
did not reach the statistical significance.
Effect of EAF on the NO level in the stomach tissue of
ethanol treated rats
The effect of the plant extracts on NO level in the gastric
homogenate was assessed using Griess reagent and
expressed as total nitrate/nitrite. The animals that were
treated with ethanol showed significant changes, with
respective decrease of NO levels (p <0.001) as compared
to the respective control animals (Table 5). Administration
of ranitidine and EAF at all the three doses showed signifi-
cant increase (p <0.05 for ranitidine and 100 mg/kg EAF;
p <0.001 for 250 and 500 mg/kg EAF, respectively) in NO
level in the stomach homogenate, parallel to the control
animals. Therefore, this finding proved the presence of
NO in the gastroprotection of EAF.
Discussion
The present study aimed to investigate the gastroprotec-
tive mechanism(s) of the most effective fraction of
Fig. 5 Effect of oral administration of vehicle (Tween 80, 8 %),
ranitidine (100 mg/kg) or EAF (100, 250 and 500 mg/kg) on gastric
wall mucus produced in the stomach. The gastric wall mucus
content (mg Alcian blue/g wet tissue) was expressed as Mean ± SEM
for 6 animals. One way ANOVA was followed by Dunnett's post hoc
test, ***p < 0.001vs. vehicle
Fig. 6 Effect of vehicle (Tween 80, 8 %, p.o.), carbenoxolone (CBX, 100 mg/kg, p.o.) and EAF (500 mg/kg, p.o) on gastric lesions induced by absolute
ethanol in rats pre-treated with saline i.p., L-NAME (70 mg/kg, i.p.) or NEM (10 mg/kg, i.p.). Each column represents the Mean ± SEM of 6
animals. One-way ANOVA followed by Newman–Keuls test, **p < 0.01,***p < 0.001 vs. saline vehicle; †††p <0.001 groups pre-treated with
L-NAME vs. vehicle L-NAME; §§ p < 0.01, §§§ p <0.001 groups pre-treated with NEM vs. vehicle NEM; ###p <0.001 saline pre-treatment vs. its
corresponding L-NAME pre-treatment; +p < 0.05, +++p < 0.001 saline pre-treatment vs. its corresponding NEM pre-treatment
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Muntingia calabura, EAF. In our previous study,
pharmacological evaluation of the three different frac-
tions of Muntingia calabura was carried out and we
have found that EAF appeared to be the most effective
fraction with high antioxidant and anti-inflammatory ac-
tivities which contribute to the prophylactic effect of the
extract against gastric ulceration in rats [30]. Therefore,
EAF was preceded to the mechanistic study to deter-
mine the underlying gastroprotective mechanism of the
fraction. For many decades, gastric secretion is known
to be a key factor in gastrointestinal functions and the
regulation of acid secretion is important in the patho-
genesis of peptic ulcer. In the current study, pylorus
ligation induced gastric ulcer model was used to study
the effect of the fraction on gastric and mucus secre-
tions. Agents that decrease secretion of gastric acid and/
or increase secretion of mucus are effective in prevent-
ing the ulcers induced by this method [43]. The ligation
of the pyloric end of the stomach causes the accumula-
tion of gastric hydrochloric acid and pepsin, resulting in
digestion of the gastric mucosa and breakdown of the
gastric mucosal barrier [44, 45]. In order to gain insight
into the effects of EAF on gastric secretion as one of the
possible mechanism contributing to its gastroprotective
actions, the gastric secretion in pylorus-ligated rats were
evaluated. Our findings demonstrated that oral adminis-
tration of EAF significantly reduced the gastric juice
volume, free and total acidity in the 6 h pylorus-ligated
rats, while exerting significant protection against lesions
formed due to accumulation of highly acidic hydrochloric
acid. Thus, the possible mechanistic activity of EAF might
be attributed to the antisecretory effect, which acts by sig-
nificantly decreasing the secretion of gastric aggressive
factors.
On the other hand, protein content of the gastric juice
increased significantly in the ulcer control group while
the treatment of EAF resulted in significant reduction in
the protein level of the stomach fluid. The elevation in
protein content of gastric juice indicates damage to the
gastric mucosa caused by plasma protein leakage into
the gastric fluid [37]. In addition, disintegration and deg-
radation of glycoprotein moieties may result in minimal
quantity of glycoprotein present in the gastric juice.
Thus, the reduction in the glycoprotein moieties may be
attributed to the decreased activity of defense mecha-
nisms, leading to gastric mucosa damage [46]. Therefore,
administration of EAF was able to decrease the plasma
proteins leakage into the gastric juice while increasing
the glycoprotein content that acts as a coating and pro-
tective barrier on the gastric mucosa.
In gastric ulcers, despite of low acid secretion,
weakening of mucosal defenses can also lead to severe
injury [10]. Therefore, gastric mucus plays a signifi-
cant role in protecting the gastric walls from the ag-
gressive factors, providing the first line of mucosal
protection against luminal acid. A continuous mucus
gel-like protective barrier coats the entire gastric
mucosa, maintaining a microenvironment at the
mucus-mucosa interface at a pH near to 7, while act-
ing as a barrier against luminal pepsin to protect the
Table 4 Effect of EAF on levels of SOD, GSH, CAT and MDA in the stomach tissue of the ethanol-treated rats
Experimental groups Dose (mg/kg) SOD (U/mg protein) Total GSH (mM/ mg protein) CAT (U/ mg protein) MDA (ng/mg protin)
Normal (untreated) - 4.90 ± 0.21** 43.35 ± 2.02*** 60.59 ± 0.87* 3.11 ± 0.14***
Vehicle + ethanol - 4.00 ± 0.13## 16.76 ± 1.73### 55.48 ± 0.76## 6.66 ± 0.26###
Ranitidine + ethanol 100 5.00 ± 0.15** 55.60 ± 1.65*** 63.87 ± 0.62*** 3.34 ± 0.18***
EAF + ethanol 100 4.74 ± 0.16* 46.48 ± 3.63*** 62.85 ± 2.31** 3.19 ± 0.16***
250 5.41 ± 0.28*** 55.72 ± 3.37*** 63.34 ± 1.12*** 2.92 ± 0.11***
500 6.22 ± 0.16*** 56.04 ± 3.26*** 65.61 ± 1.28*** 2.86 ± 0.10***
Values are expressed as mean ± SEM for six animals in each group. One way ANOVA was followed by Dunnett's post hoc test, *p < 0.05, **p < 0.01, and ***p < 0.001 as
compared to the vehicle group. Student’s t-test was performed for comparing normal and vehicle groups, significant at ##p < 0.01, and ###p < 0.001
Table 5 Effect of EAF on levels of PGE2 and NO in the stomach tissue of the ethanol-treated rats
Experimental groups Dose (mg/kg) Prostaglandin E2(pg/mg protin) NO (μM/g tissue)
Normal (untreated) - 188.39 ± 4.66** 43.06 ± 4.83**
Vehicle + ethanol - 159.90 ± 6.49## 22.25 ± 1.65##
Ranitidine + ethanol 100 186.88 ± 3.39** 45.73 ± 4.22**
EAF + ethanol 100 178.12 ± 5.07 42.61 ± 2.25**
250 191.94 ± 5.24*** 47.25 ± 4.46***
500 201.07 ± 4.20*** 56.47 ± 4.61***
Values are expressed as mean ± SEM for six animals in each group. One way ANOVA was followed by Dunnett's post hoc test, *p < 0.05, **p < 0.01, and ***p < 0.001 as
compared to the vehicle group. Student’s t-test was performed for comparing normal and vehicle group, significant at##p < 0.01
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underlying mucosa from proteolytic digestion [47].
The mucus consists of mucin-type glycoproteins,
which are detected by amounts of Alcian blue bind-
ing. Our results showed that EAF treatment aug-
mented the amount of adhered gastric mucus as
compared to the vehicle. An increase in mucus secre-
tion may be responsible for the gastric cytoprotection
by improving the buffering of acid in gastric juice
and acting as an effective barrier to the back diffusion
of hydrogen ions as well as reducing stomach wall
friction during peristalsis and gastric contractions
[48]. Thus, it could be postulated that increase in
mucus secretion by EAF play an important role in
gastric mucosal protection and it could be one of the
potential mechanisms of the gastroprotective effect
elicited by EAF.
Overall, the results obtained in the pyloric ligature
model demonstrated the significant potential of EAF as
an effective gastroprotective agent. Treatment of EAF in
this model proves to weaken the gastric aggressive fac-
tors while improve the cytoprotective factor, which is via
reduction in the volume, free and total acidity of gastric
secretion and enhanced mucus secretion to strengthen
the gastric mucosal barrier, respectively. EAF also aug-
mented the pH value of the gastric fluid eventhough
they were not significantly different as compared to the
control group.
In order to evaluate the involvement of endogenous
NO and SH compounds in the gastroprotective effect of
EAF, L-NAME or NEM were pre-treated to rats that
were lesion-induced with ethanol. NO is a ubiquitous
molecule generated by nitric oxide synthase (NOS) and
is involved in a variety of biological processes. In our
current study, administration of L-NAME, a non-
selective NOS inhibitor, aggravated lesion formation
when induced by ethanol. L-NAME inhibits NO synthe-
sis while causing vasoconstriction of several vascular
beds and increases systemic blood pressure, resulting in
damage to gastric mucosa and its endothelium [49]. Our
results show an increase in gastric lesions when NO pro-
duction is blocked before EAF treatment. Pre-treatment
of the animals with L-NAME reversed the gastroprotec-
tive effects exerted by EAF against ethanol-induced
damage, suggesting that the gastroprotective effect of
the EAF could be mediated by the NO pathway. On the
other hand, we have also showed the possible involve-
ment of NO in gastroprotection exerted by EAF by de-
termining the NO level in the stomach tissue of the rats
induced with ethanol. Ethanol effectively reduced the
level of NO in the gastric mucosa as compared to the
control group which could be a result of decreased NOS
activity that was associated with an increase in the ex-
tent of damage. This finding is in accordance with Haj-
rezaie et al. [50], Nordin et al. [51] and Rouhollahi et al.
[52]. Low levels of NO could also be due to the con-
sumption of NO in the free radical reactions, resulting
in overproduction of peroxynitrites (ONOO−) during
ethanol metabolism [53]. According to Rouhollahi et al.
[52], formation of gastric lesions induced by ethanol is
remarkably abolished by NO-stimulating drugs, while a
reduction in NO synthesis could increase the suscepti-
bility of the gastric mucosa to the destructive effects of
ethanol. In our study, EAF exerted a significant protect-
ive mechanism by increasing the levels of NO in the
EAF treated stomach tissue. The increased levels of NO
play an important role in gastric protection through the
dilation of gastric blood vessels. This result in an in-
creased supply of nutrients that contributes to the multi-
plication of cells that constitute the granulation tissue,
which is the first tissue formed in the regeneration
process [8]. Thus, the gastroprotective effect afforded by
EAF could be associated with the involvement and
modulation of NO, which results in protection of gastric
mucosa against damage induced by noxious agent such
as ethanol.
Furthermore, the administration of NEM, a SH-
blocker, significantly increased the effects of ethanol on
gastric mucosa injury, reversing the gastroprotective ef-
fect of EAF. The absence of SH group following the
NEM administration reduces the extract’s ability to exert
gastroprotective activity. Endogenous SH compounds
play a critical role in maintaining gastric mucosal integ-
rity and they are believed to be the key agents in muco-
sal protection against ethanol-induced gastric injury. Its
continuous adherence to mucus layer is a barrier to lu-
minal pepsin and creates a stable, undisturbed layer to
support the surface neutralization of acid. This prevents
the proteolytic digestion of the underlying mucosa [47].
SH compound also unites the mucus subunits, forming
disulfide bridges, which prevents the mucus from be-
coming water-soluble and easily withdrawn by ulcero-
genic agents, such as ethanol [54]. Besides that, the SH-
groups have the ability to bind the free radicals gener-
ated by noxious agents and act as recycling antioxidants,
thus controlling the production and nature of mucus [6,
55]. Therefore, our results suggest that the gastroprotec-
tive effect of EAF involves a strong participation of the
SH- compounds, indicating the importance of an intact
sulfhydryl barrier that is relevant in the mucosal protec-
tion against harmful injuries.
In our previous study, we have proved that EAF was
able to markedly ameliorate gastric ulceration in
ethanol-induced rats [30]. Hence, in our current study,
the mechanisms involving enzymatic and non-enzymatic
systems including SOD, CAT, GSH and MDA, have been
investigated and their involvements are proven. Ethanol
administration increases lipid peroxidation, decreases
SOD, CAT, GSH levels and the protective factors of the
Zakaria et al. BMC Complementary and Alternative Medicine  (2016) 16:78 Page 12 of 17
gastric mucosa. SOD, CAT and GSH, are the mutually
supportive team of antioxidant enzymes, providing an
effective defense system against ROS. SOD is considered
to be the first line of defense against the deleterious ef-
fect of ROS in cells. It catalyzes the dismutation of
superoxide radical (O−) to either ordinary molecular
oxygen (O2) or hydrogen peroxide H2O2 [56]. In our
study, administration of ethanol was shown to inhibit
SOD activity. This may cause an interruption in conver-
sion of the O− radicals resulting in an increased flux of
O− in cellular compartments [57]. This may cause an in-
crease in oxidative degradation of lipids, known as lipid
peroxidation, where the O- radicals may attract electrons
from the lipids in cell membranes, resulting in cell dam-
age. Hence, the increased lipid peroxidative indices in
our current study that was proved via the MDA assay
could be associated with the reduced SOD levels. MDA
is the final product of lipid peroxidation. It is widely
used as a marker to determine the level of lipid peroxi-
dation [51]. Lipid peroxidation occurs when the acti-
vated ROS attacks the unsaturated fatty acids of cell
membrane phospholipids, causing damage to the mem-
brane phospholipid, leading to cell injury [58]. In our
present study, an increment in MDA level was observed
in the stomach of ethanol-ulcerated rats. This indicates
the enhanced lipid peroxidation and over production of
free radicals, which results in tissue damage and failure
of the antioxidant defense mechanisms to inhibit exces-
sive free radicals formation. Oral administration of EAF
was able to significantly reverse these changes and mark-
edly reduced concentration of MDA, thus suggesting
that the mechanism of gastroprotection of EAF could be
due to its antiperoxidative potential by virtue of its free
radical scavenging activity. Meanwhile, CAT is a heme-
protein, which catalyzes the reduction of H2O2 and pro-
tects the tissue from highly reactive oxygen free radicals
and hydroxyl radicals [9]. CAT also acts as preventive
antioxidant that triggers the rapid conversion of peroxyl
radical into biologically safe substances, such as water
[59]. CAT activity was increased in the EAF or ranitidine
treated rats, but the activity was decreased when given
ethanol alone. A reduction in CAT level may interrupt
the degradation of H2O2 that was produced from the
dismutation of O- radicals by SOD. On the other hand,
GSH, the non-enzymatic biological antioxidant found
abundantly in the gastric mucosa of humans and rats,
plays an important role in removing H2O2, superoxide
anions and alkoxy radicals with a consequence of attenu-
ating tissue damage [9]. GSH also helps in maintaining
the mucosal integrity. The depletion of GSH is associ-
ated with the accumulation of highly reactive free radi-
cals, which results in loss of function and integrity of
cell membranes [60]. Hence, the reduction in GSH level
in group that received only ethanol and the reversal
effect of EAF or ranitidine suggest that the gastroprotec-
tive activity of EAF may appear through participation of
GSH. On the whole, the oral administration of EAF nor-
malized gastric mucosal levels of SOD, MDA, CAT and
GSH in response to oxidative stress caused by ethanol.
Thus, our findings clearly demonstrate the significant
role played by the antioxidant actions of EAF in counter-
acting the detrimental effect evoked by ethanol in the di-
gestive system.
Furthermore, the role of PGE2 in mediating the gastro-
protective effect of EAF was also investigated. The level
of PGE2 dropped in the ulcer control group, as adminis-
tration of ethanol may reduce the synthesis of PGE2 in
gastric mucosa. However, the level of PGE2 was elevated
following the treatment of EAF, suggesting that the gas-
troprotective effect of EAF could be mediated by PGE2.
In the stomach, prostaglandins play a vital protective
role by improving blood flow to maintain the cellular in-
tegrity in the mucosa, stimulate mucus secretion and
enhance secretion of bicarbonate and SH compounds to
strengthen the resistance of gastric mucosal cells to the
necrotizing effect of strong irritants [1, 61]. In addition,
prostaglandins also help to regulate mucosal cell turn-
over and repair, while suppressing the aggressive factors,
such as acid and pepsin secretion [62]. Besides that, ac-
cording to Heeba et al. [63], the prostaglandins influence
virtually every component of the mucosal defense, which
includes inhibiting leukocyte recruitment and enhancing
the resistance of epithelial cells against potential damage
by cytotoxins. The increase in mucosal generation of
PGE2 observed after treatment with EAF probably medi-
ated, at least in part, by NO. As reported above, the gas-
troprotective activity of EAF possibly involves the
modulation of NO and NO has been reported to in-
crease PGE2 biosynthesis through a cyclic guanosine
monophosphate independent-mechanism. Hence, it
could be assumed that NO might involve in the regula-
tion of PGE2 biosynthesis and/or release in the stomach
after damage [64].
The gastroprotective potential of EAF could also be at-
tributed to the presence of quercetin and gallic acid,
from the class of flavonoid and phenolic acid, respect-
ively. In the present study, we have showed the presence
and quantified both quercetin and gallic acid in EAF.
Quercetin is the most powerful flavonoid, which affords
protection against ROS and reactive nitrogen species
(RNS) produced during the normal oxygen metabolism
or induced by exogenous damage in the body [65].
Quercetin is widely studied and has been shown to pos-
sess significant antiulcer and gastroprotective activity
and has been found to protect gastric mucosa against
ethanol, acetic acid, acid ethanol, ischemia/reperfusion,
stress, pylorus ligation, reserpine, indomethacin and
Helicobacter pylori [7, 66–72]. The best described
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property of quercetin is its ability to act as antioxidants,
which include enzymatic and non-enzymatic antioxi-
dants that control the level of ROS/RNS and repair oxi-
dative cellular damages. The antioxidant mechanisms
involved in the gastroprotective effect of quercetin in-
clude inhibition of lipid peroxidation, reduction of pro-
tein carbonyl compounds and increase in the SOD
activity as well as enhance the levels of mucosal non-
protein SH compounds in gluthathione peroxidase activ-
ity [67, 68, 73]. Hu et al. [74], quercetin was reported to
protect H2O2-induced oxidative damage in human gas-
tric epithelial cells and ameliorate ROS production in
acute gastric injury in mice. This clearly supports our
findings of increased SOD and GSH levels and reduced
MDA activity in the stomach homogenate treated with
EAF. Besides, quercetin is able to inhibit acid production
in isolated parietal cells in response to histamine and
dibutyryl-cAMP stimulation and also acts in preventing
H+/K+-ATPase activity [75]. Hence, the gastroprotective
effect of quercetin could be due to its antiperoxidative,
antioxidant and antihistaminic effects.
On the other hand, gallic acid is a naturally abundant
polyhydroxy phenolic compound consumed as dietary
herbal supplement [76]. Sen et al. [77] have showed that
gallic acid exerts its antiulcer effect in aspirin plus pyl-
orus ligation-induced gastric lesion by attenuating the
offensive factors and increasing the mucosal defensive
factors, while activating the antioxidant mechanisms and
inhibiting toxic oxidant mechanisms in stomach tissues.
Another recent study by Abdelwahab [78] revealed the
gastroprotective mechanism of gallic acid in ethanol-
induced ulcerogenesis. Abdelwahab has claimed that the
major mechanism of action of gallic acid as an antiulcer
agent is due to their effects on gastric acid secretion,
promotion of mucosal protection by endogenous factors
(NO, PGE2 and tumor necrosis factor-α), inhibition of
oxidative stress-induced apoptosis, prevention of proin-
flammatory cytokines production and inhibition of hista-
mine release from mast cells. Yen et al. [79] has
reported the excellent antioxidant activity of gallic acid.
Therefore, it is plausible to suggest that the gastropro-
tective activity of PEF, EAF and MEMC could be due to
the presence of quercetin and gallic acid. However, EAF
showed to contain the highest amount of quercetin and
gallic acid, followed by MEMC and PEF, which may ex-
plain the reason why EAF stands out to be the most ef-
fective fraction affording its gastroprotective activity as
compared to the other extracts.
The UHPLC-ESI analysis of Muntingia calabura frac-
tion proved the presence of quercetin and gallic acid via
the MS analysis. In addition, we have also detected the
presence of 20 other compounds in the fraction. Among
them, pinocembrin, pinostrobin, pinobaksin, chyrsin,
and ermanin has been reported previously to be present
in the leaves of Muntingia calabura [80]. Meanwhile, we
have revealed, for the first time, the presence of few
other flavonoids, which could contribute to the gastro-
protective action of Muntingia calabura. They include
protocatechuic acid, ferulic acid, quercitrin-2″-O-gall-
ate, pentagalloyl-hexoside II, kaempferol-3-O-galacto-
side, myricetin, isoferulic acid, afzelin-O-gallate,
kaempferol-3-O-glucoside, rhamnetin, kaempferol and
kaempferide. Protocatechuic acid is a type of widely
distributed naturally occurring phenolic acid, which is
similar to gallic acid, caffeic acid, vanillic acid, and
syringic acid that are well-known antioxidant com-
pounds. Protocatechuic acid ethyl ester was found to
possess significant antiulcer property in ethanol, as-
pirin or pyloric-ligation induced gastric lesions in rats.
The mechanism of action of protocatechuic acid ethyl
ester may be due to either cytoprotective action of
the drug or by strengthening the gastric mucosa
thereby enhancing mucosal defense [81]. Similar to
several other phenols, ferulic acid also exhibits anti-
oxidant activity in response to free radicals, resulting
in strong anti-inflammatory activity [82]. A very re-
cent study showed that quercitrin, afzelin and isoferu-
lic acid were able to significantly reduce gastric
ulceration in HCl/ethanol-induced rats as these com-
pounds are able to act as free radical scavengers and
some of them were found to increase the mucosal
content of prostaglandin in tissues, affording protec-
tion to the gastric mucosa against various ulcerogens.
Besides, isoferulic acid was also reported to possess
strong antioxidant properties while able to effectively
inhibit lipid peroxidation [83]. Furthermore, quercitrin
2′-O-gallate were reported to exhibit moderate to
strong radical scavenging properties on lipid peroxida-
tion, hydroxyl radical, superoxide anion generation
and DPPH radical [84]. Kaempferol has been reported
to exert significant antiulcer activity in ethanol-,
stress- and pylorus-ligation-induced ulcer models
while myricetin was found to be active in reserpine-
and stress-induced ulcer models [7]. Kaempferol
causes a decrease in acid-pepsin secretion and in-
crease in mucin secretion, while increasing endogen-
ous prostaglandins and decreasing leukotrienes [85].
Conclusion
In conclusion, our current findings suggest that EAF ex-
erts its gastroprotective activity via several mechanisms.
The antisecretory effect via reduction in the volume, free
and total acidity and the strengthening of gastric muco-
sal barrier via enhancement in mucus secretion suggests
the balanced protection of EAF against the aggressive
and defensive factors of gastric ulcer. Another under-
lying mechanism of gastroprotection of EAF may involve
the modulation of NO and SH compounds, which are
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two important components that play important role in
gastric mucosal protection. Besides, the gastroprotective
activity of EAF against oxidative injuries caused by etha-
nol is most likely due to its strong antioxidant and anti-
peroxidative properties as EAF augments the activities of
CAT, SOD and GSH, and attenuates the MDA level in
stomach tissues, respectively. Moreover, an increase in
PGE2 level suggests that the protective effect of EAF
could also be mediated by PGE2. The presence of vari-
ous flavanoids found in EAF could explain the effective-
ness and the best activity of this fraction in affording
protection against gastric damages. Therefore, our ex-
perimental findings render EAF as a promising constitu-
ent for the protection from gastric ulcer. Furthermore,
the elucidation of the underlying mechanisms of action
also places the traditional use of Muntingia calabura
leaves in gastroprotection on a solid scientific footing.
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